Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

February 3, 2022 09:34 AM EST

Opinion: A placebo-controlled trial requirement from CMS will spell the end of Biogen's controversial Alzheimer's drug

Zachary Brennan

Senior Editor

With just $3 million in 2021 sales for Biogen’s controversial new Alzheimer’s drug, $225 million in Aduhelm inventory sitting on shelves, and hundreds of millions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Opinion: A placebo-controlled trial requirement from CMS will spell the end of Biogen's controversial Alzheimer's drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

Biohaven lands priority review on second-chance application for neurodegenerative drug

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Opin­ion: A place­bo-con­trolled tri­al re­quire­ment from CMS will spell the end of Bio­gen's con­tro­ver­sial Alzheimer's drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Opinion: A placebo-controlled trial requirement from CMS will spell the end of Biogen's controversial Alzheimer's drug